Faculty profile

Stephen Pautler

ResearcherMedical BiophysicsWestern University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Western University directory, so their courses may be missing. Find their university profile.

Stephen Pautler

Researcher

Medical Biophysics

Health Sciences

Western University

London, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
7 publications in the last five years, latest in 2025.
Principal investigator on 1 research grant (1 CIHR), most recently in 2023.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

101

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

University Profile Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their Western University profile.

Adjuvant Therapy Clinical Decision Support Digital Histopathology Machine Learning Prostate Cancer

Latest papers

Ablative Yttrium-90 Radioembolization Therapy for Nonmetastatic Renal Cell Carcinoma (ARRCC) Phase II Trial.
Journal of vascular and interventional radiology : JVIR · 2025
Renal cell carcinoma with fibromyomatous stroma (RCC FMS) and with hemangioblastoma-like areas is part of the RCC FMS spectrum in patients with tuberous sclerosis complex.
Histopathology · 2025
Evaluating trends in radical prostatectomy approach and 30-day complication rate in Ontario from 2010-2019.
Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025

All 28 publications

Latest funding

Histopathology image analysis for prostate cancer prognosis after radical prostatectomy
CIHR · 2023 · Principal investigator
$592,876
Prostate-targeted PET/TRUS dual-modality imaging system for diagnosis and image-guided biopsy.
CIHR · 2022 · Co-investigator
$738,226
Program for Image-guided Minimally Invasive Surgery and Therapy (PI-MIST)
CIHR · 2014 · Co-investigator
$2,274,483

All 3 grants and awards

28 publications.

Ablative Yttrium-90 Radioembolization Therapy for Nonmetastatic Renal Cell Carcinoma (ARRCC) Phase II Trial.

Cool DW, Cardarelli Leite L, Laidley D, Romsa J, Mujoomdar A, Inman B, Pautler S, Correa R, Huynh M

Journal of vascular and interventional radiology : JVIR2025

DOI: 10.1016/j.jvir.2025.05.029 PMID: 40472966

Renal cell carcinoma with fibromyomatous stroma (RCC FMS) and with hemangioblastoma-like areas is part of the RCC FMS spectrum in patients with tuberous sclerosis complex.

Baranova K, Houpt JA, Arnold D, House AA, Lockau L, Ninivirta L, Pautler S, Chen H, Moussa M, Saleeb R, Gomez JA, Yilmaz A, Siadat F, Box A, Mahoney DJ, Zemp FJ, Gabril M, Trpkov K

Histopathology2025

DOI: 10.1111/his.15505 PMID: 40590246

Evaluating trends in radical prostatectomy approach and 30-day complication rate in Ontario from 2010-2019.

Motamedi N, McClure A, Power N, Pautler S, Gien L, Welk B, McGee J

Canadian Urological Association journal = Journal de l'Association des urologues du Canada2025

DOI: 10.5489/cuaj.8636 PMID: 39418489

Association of marginalization and PSMA-PET in prostate cancer: An analysis of the Ontario PSMA-PET Registry for Recurrent Prostate Cancer

Tan VS, Metser U, Rashid M, Langer DL, MacCrostie P, Green B, Mak V, Kulkarni GS, Shayegan B, Pautler S

Journal of the Canadian Urological Association20252 citations

DOI: 10.5489/cuaj.9034

The impact of the Ontario quality-based procedures funding model on radical prostatectomy outcomes.

Motamedi N, McClure A, Power NE, Pautler S, Given L, Welk B, McGee J

Canadian Urological Association journal = Journal de l'Association des urologues du Canada2024

DOI: 10.5489/cuaj.8632 PMID: 39190172

Targeting prostate lesions on multiparametric MRI with HDR brachytherapy: Optimal planning margins determined using whole-mount digital histology.

Smith CW, Marcus T, Hoover D, Surry K, D'Souza D, Cool D, Kassam Z, Bastian-Jordan M, Gómez JA, Moussa M, Chin JL, Pautler S, Bauman GS, Ward AD

Brachytherapy2022

DOI: 10.1016/j.brachy.2022.01.009 PMID: 35337747

Prostate cancer classification using radiomics and machine learning on mp-MRI validated using co-registered histology.

Alfano R, Bauman GS, Gomez JA, Gaed M, Moussa M, Chin J, Pautler S, Ward AD

European journal of radiology2022

DOI: 10.1016/j.ejrad.2022.110494 PMID: 36095953

Short-duration dynamic [18F]DCFPyL PET and CT perfusion imaging to localize dominant intraprostatic lesions in prostate cancer: validation against digital histopathology and comparison to [18F]DCFPyL PET/MR at 120 minutes.

Yang DM, Alfano R, Bauman G, Thiessen JD, Chin J, Pautler S, Moussa M, Gomez JA, Rachinsky I, Gaed M, Chung KJ, Ward A, Lee TY

EJNMMI research2021

DOI: 10.1186/s13550-021-00844-0 PMID: 34652551

Prostate specific membrane antigen positron emission tomography for lesion-directed high-dose-rate brachytherapy dose escalation.

Smith CW, Alfano R, Hoover D, Surry K, D'Souza D, Thiessen J, Rachinsky I, Butler J, Gomez JA, Gaed M, Moussa M, Chin J, Pautler S, Bauman GS, Ward AD

Physics and imaging in radiation oncology2021

DOI: 10.1016/j.phro.2021.07.001 PMID: 34589619

The value of 99mTc-sestamibi single-photon emission computed tomography-computed tomography in the evaluation and risk stratification of renal masses.

Sistani G, Bjazevic J, Kassam Z, Romsa J, Pautler S

Canadian Urological Association journal = Journal de l'Association des urologues du Canada2021Senior author

DOI: 10.5489/cuaj.6708 PMID: 33212002

Something wrong or missing on this profile? Suggest a correction

Stephen Pautler

Research

Latest papers

Latest funding

Ablative Yttrium-90 Radioembolization Therapy for Nonmetastatic Renal Cell Carcinoma (ARRCC) Phase II Trial.

Renal cell carcinoma with fibromyomatous stroma (RCC FMS) and with hemangioblastoma-like areas is part of the RCC FMS spectrum in patients with tuberous sclerosis complex.

Evaluating trends in radical prostatectomy approach and 30-day complication rate in Ontario from 2010-2019.

Association of marginalization and PSMA-PET in prostate cancer: An analysis of the Ontario PSMA-PET Registry for Recurrent Prostate Cancer

The impact of the Ontario quality-based procedures funding model on radical prostatectomy outcomes.

Targeting prostate lesions on multiparametric MRI with HDR brachytherapy: Optimal planning margins determined using whole-mount digital histology.

Prostate cancer classification using radiomics and machine learning on mp-MRI validated using co-registered histology.

Short-duration dynamic [18F]DCFPyL PET and CT perfusion imaging to localize dominant intraprostatic lesions in prostate cancer: validation against digital histopathology and comparison to [18F]DCFPyL PET/MR at 120 minutes.

Prostate specific membrane antigen positron emission tomography for lesion-directed high-dose-rate brachytherapy dose escalation.

The value of 99mTc-sestamibi single-photon emission computed tomography-computed tomography in the evaluation and risk stratification of renal masses.

Histopathology image analysis for prostate cancer prognosis after radical prostatectomy

Prostate-targeted PET/TRUS dual-modality imaging system for diagnosis and image-guided biopsy.

Program for Image-guided Minimally Invasive Surgery and Therapy (PI-MIST)

Frequent collaborators

Blayne Welk

Glenn Bauman

Antonio Finelli

Jacob McGee

Nicholas Power

Melissa Huynh

John F Valliant

Rahul Bansal

Alan So

Ting-Yim Lee

Wassim Kassouf

Aaron Ward

John Denstedt

Brant Inman

Hassan Razvi

Olli Saarela

Manal Gabril

Jonathan Thiessen

Jennifer Bjazevic

Sumit Dave

Martin Gleave

Patrick Richard

Aly-Khan Lalani

Rola Saleeb

Neil Fleshner

Philippe Violette

Ilias Cagiannos

Aaron Fenster

Bobby Shayegan